Citations to this article
Citation Information: JCI Insight. 2021;6(16):e149819. https://doi.org/10.1172/jci.insight.149819.
Abstract
Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor T cells (UCART7) can lead to profound immune deficiency due to loss of normal T and NK cells. While a small population of endogenous CD7– T cells exists, these cells are unlikely to be able to repopulate the entire immune repertoire after UCART7 treatment, as they are limited in number and proliferative capacity. To rescue T and NK cells after UCART7, we created hematopoietic stem cells genetically deleted for CD7 (CD7-KO HSCs). CD7-KO HSCs were able to engraft immunodeficient mice and differentiate into T and NK cells lacking CD7 expression. CD7-KO T and NK cells could perform effector functions as robustly as control T and NK cells. Furthermore, CD7-KO T cells were phenotypically and functionally distinct from endogenous CD7– T cells, indicating that CD7-KO T cells can supplement immune functions lacking in CD7– T cells. Mice engrafted with CD7-KO HSCs maintained T and NK cell numbers after UCART7 treatment, while these were significantly decreased in control mice. These studies support the development of CD7-KO HSCs to augment host immunity in patients with T cell malignancies after UCART7 treatment.
Authors
Miriam Y. Kim, Matthew L. Cooper, Miriam T. Jacobs, Julie K. Ritchey, Julia Hollaway, Todd A. Fehniger, John F. DiPersio
Citations to this article (20)
| Title and authors | Publication | Year |
|---|---|---|
|
Advances in CAR-T-cell therapy in T-cell malignancies
Zheng R, Zhu X, Xiao Y |
Journal of Hematology & Oncology | 2024 |
|
Stable engraftment, as well as graft versus host disease‐free and relapse‐free survival brought by the combination of CD7 targeted universal chimeric antigen receptor‐T, and donor hemopoietic stem cells: Indication of a case report
Li S, Yuan Z, Liu L, Li Y, Luo L, Peng L, Xu M, Yin P, Chen Y, Li X, Zang Q, Zhang X, Wang S |
2024 | |
|
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
Wellhausen N, Baek J, Gill SI, June CH |
Nature reviews. Cancer | 2024 |
|
Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
Jing J, Ma Y, Xie Z, Wang B, Chen Y, Chi E, Wang J, Zhang K, Wang Z, Li S |
Frontiers in Immunology | 2024 |
|
CAR T-cell therapy in acute myeloid leukemia.
Almotiri A |
Saudi medical journal | 2024 |
|
Application of novel CAR technologies to improve treatment of autoimmune disease.
Cheever A, Kang CC, O'Neill KL, Weber KS |
Frontiers in immunology | 2024 |
|
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Zheng H, Zhao H, Han S, Kong D, Zhang Q, Zhang M, Chen Y, Zhang M, Hu Y, Huang H |
Experimental Hematology & Oncology | 2024 |
|
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
Gierschek F, Schlueter J, Kühnel I, Feigl FF, Schmiedel D, Prüfer M, Buchinger L, Cerwenka A, Cappel C, Huenecke S, Köhl U, Wels WS, Ullrich E |
Transfusion Medicine and Hemotherapy | 2024 |
|
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, Kang Y, Xu J, Wu Z, Wang X, Huang Z, Zhang Y, Wu D, Chang AH, Hu Y, Mei H |
Blood Cancer Journal | 2023 |
|
Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, Lu W, Zhao M |
Frontiers in immunology | 2023 |
|
CD7 protein plays a crucial role in T cell infiltration in tumors
Sheng B, Zhang K, Tian S, Ma R, Li Z, Wu H, Wang T, Jiang L, You F, An G, Meng H, Yang L, Liu X |
Heliyon | 2023 |
|
Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case Report
Han Y, Yao H, He GC, Lai SH, Deng Y, Zhang S, He Y, Xiong YS, Chang AH, Su Y, Yi H |
Frontiers in immunology | 2023 |
|
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy
Wellhausen N, O\u2019Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, Gill SI |
Science Translational Medicine | 2023 |
|
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY, O\u2019 Neal J, Ritchey JK, Rettig MP, Gao F, Rettig G, Turk R, Lee BH, Cooper ML, DiPersio JF |
Leukemia | 2023 |
|
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A |
Frontiers in immunology | 2023 |
|
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG, Patel RP, Ruella M, Barta SK |
2023 | |
|
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
Huang J, Huang X, Huang J |
Frontiers in immunology | 2022 |
|
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, Cui Q, Mu Q, Chen G, Han L, Guo T, Cui J, Jiang X, Zheng X, Yu S, Li X, Zhang X, Chen M, Li X, Gao M, Wang K, Zu C, Zhang H, He X, Wang Y, Wang D, Ren J, Huang H |
Cell Research | 2022 |
|
Chimeric antigen receptor T-cell therapy for T-ALL and AML
Wei W, Yang D, Chen X, Liang D, Zou L, Zhao X |
Frontiers in Oncology | 2022 |
|
Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, Patil SL, Khanlari M, Inaba H, Klco JM, Mullighan CG, Krenciute G, Chockley PJ, Naik S, Langfitt DM, Mamonkin M, Obeng EA, Thomas PG, Gottschalk S, Velasquez MP |
Blood | 2022 |
